SCHEMBL6891750

SCHEMBL6891750

Nc1c(Br)c(N2CCS(=O)(=O)CC2)nc2c(-c3cnc4ccccc4c3)cnn12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.36
FGFR2 P21802 3/20 0.36
CHEK1 O14757 5/20 0.36
CCNA2 P20248 5/20 0.36
CDK2 P24941 5/20 0.36
CCNA1 P78396 5/20 0.36
MEN1 O00255 2/20 0.34
NPC1 O15118 2/20 0.34
KMT2A Q03164 2/20 0.34
BIRC5 O15392 1/20 0.34
RAB9A P51151 1/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
PIK3CA P42336 2/20 0.33
SLC2A1 P11166 1/20 0.33
PDE10A Q9Y233 1/20 0.33
HTR3A P46098 1/20 0.33
LCK P06239 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6894955 0.96 EGFR (0.34) EGFRFGFR2CHEK1CCNA2CDK2
SCHEMBL10234371 0.89 KMT2A (0.36) CHEK1CCNA2CDK2CCNA1MEN1
SCHEMBL10234368 0.89 CHEK1 (0.38) EGFRCHEK1CCNA2CDK2CCNA1
SCHEMBL7882617 0.89 KMT2A (0.36) CHEK1CCNA2CDK2CCNA1MEN1
SCHEMBL10234358 0.88 CHEK1 (0.35) EGFRCHEK1CCNA2CDK2CCNA1
SCHEMBL10234375 0.87 CDK2 (0.38) CHEK1CCNA2CDK2CCNA1MEN1
SCHEMBL6893430 0.87 NPC1 (0.44) MEN1NPC1KMT2ARAB9APIK3CA
SCHEMBL6893394 0.87 CHEK1 (0.37) EGFRFGFR2CHEK1CCNA2CDK2
SCHEMBL6891730 0.86 AKT1 (0.35) EGFRFGFR2CHEK1CCNA2CDK2
SCHEMBL10238625 0.86 CHEK1 (0.36) CHEK1CCNA2CDK2CCNA1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 EGFR 4536/4885FGFR2 3710/4885CHEK1 2755/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR EGFR 2799/4885FGFR2 1827/4885CHEK1 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.